All News

CPPDwrist.JPG

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

d Jack Cush, MD

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.

Read Article
Balance Empathy Emotional Heart

Best of 2023: How Being a Patient Taught Me to Be a Better Doctor

d Marcela Ferrada, MD

When I was accepted into medical school, my Dad (a trauma surgeon) taught me that as a doctor I should not judge and do my best not to let my personal views interfere with how I manage and interact with my patients.

Read Article
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies, 4661 pts. Corticosteroids reduced mortality in more severe CAP(RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/1QbuCZRXze https://t.co/16qiqIatJq

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK

Links:

Dr. John Cush RheumNow ( View Tweet)

Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/vZALPMU8lI https://t.co/yGvDLHIp5y

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is just about a month away--will we see you there? You can attend virtually or in-person at our Dallas, TX location. With over 20 dynamic speakers, we are confident you'll leave feeling inspired! https://t.co/y6BVvZDcku https://t.co/NqzkVd3l8p

Links:

Dr. John Cush RheumNow ( View Tweet)
How Being a Patient Taught Me to Be a Better Doctor” Dr. Marcella Ferrada (@maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/BZPlLzdSsk https://t.co/Ykh6AhAnxn

Links:

Dr. John Cush RheumNow ( View Tweet)
Browse through this update to learn more about the real impact of comorbidities on patients living with SpA. Sponsored by Novartis Medical Affairs. https://t.co/0BCVvTYzAl https://t.co/2RhJomr6Dr

Links:

Dr. John Cush RheumNow ( View Tweet)
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/IagcDC24rZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2023 - Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Uh2RFrfpc2

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain &; odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/IcIQwP9z7C

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB

Links:

Dr. John Cush RheumNow ( View Tweet)
Study compared 491 SLE pts tested for ANCA Abs w/ 171 ANCA-associated vasculitis (AAV) pts. 46 SLE pts were ANCA+. ANCA-positive LN have worse baseline renal function and lower protein remission rates . https://t.co/fQCkBXJpO4

Links:

Dr. John Cush RheumNow ( View Tweet)

200 Biologic naive #RA pts in remission under csDMARD tapering and withdrawal while given either placebo or oral curcumin (1 g bid). Flare-free survival at 52 wks was similar between groups (60% vs 64%; p = 0.76). Time to flare was similar (219d vs 214d) https://t.co/m3j8HmjTT3 https://t.co/jDoAYN0eKQ

Links:

Dr. John Cush RheumNow ( View Tweet)

SGLT2 Inhibitors as Gout Treatment. Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said. https://t.co/zJVJuvCoIm https://t.co/kDLJynYczc

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Great Rheum Meetings What makes for a great Rheumatology CME meeting? https://t.co/tdb2crz8XP https://t.co/ZnMIhZpejO

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/szffvXtwaS

Links:

Dr. John Cush RheumNow ( View Tweet)

Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/WZcJugj3Bg https://t.co/HQ3Xg9h0md

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×